Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Clinical trial NCT04579380 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04579380
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Uterine Neoplasms Uterine Cervical Neoplasms Biliary Tract Neoplasms Urologic Neoplasms Carcinoma, Non-Small-Cell Lung HER2 Mutations Breast Neoplasms

Start date: 2021-01-11
Primary completion: 2023-11-01
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.